Updates in the management of patients with acute coronary syndrome.
- Author:
Jong Shin WOO
1
;
Myeong Kon KIM
Author Information
1. Division of Cardiology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
- Publication Type:Review ; Clinical Trial
- Keywords:
Acute coronary syndromes;
Treatment;
Secondary prevention;
Antiplatelet agents;
Anticoagulants
- MeSH:
Acute Coronary Syndrome;
Angina, Unstable;
Anticoagulants;
Early Diagnosis;
Humans;
Life Style;
Myocardial Infarction;
Platelet Aggregation Inhibitors;
Recurrence;
Risk Factors;
Secondary Prevention;
Troponin
- From:Korean Journal of Medicine
2009;76(6):661-676
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Acute coronary syndrome (ACS) represents a broad spectrum of ischemic myocardial events, including unstable angina, non-ST elevation myocardial infarction, and acute ST elevation myocardial infarction, which are associated with high morbidity and mortality. Early diagnosis and risk stratification are essential for initiation of optimal medical and invasive management. Randomized clinical trials over the past decade have revolutionized the care of patients with ACS. Therapeutic measures consist of administration of aggressive antiplatelet, antithrombotic, and antiischemic agents. In addition, patients with high-risk features, notably positive troponin, ST segment changes, and diabetes, benefit from early invasive intervention as compared to conservative strategies. Lifestyle interventions, modification of risk factor profile, and long-term medical treatment are of pivotal importance in reducing the long-term risk of recurrence.
